ArticleOncology letters2016
Expression and clinical significance of glucose transporter-1 in pancreatic cancer.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic value of glycolysis markers in pancreatic cancer: A systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- Prognostic role of glycolysis for cancer outcome: evidence from 86 studies.Journal of cancer research and clinical oncology · 2019Pooled it
- Prognostic value of GLUT-1 expression in pancreatic cancer: results from 538 patients.Oncotarget · 2017Pooled it
- Review
- Primary ovarian neuroendocrine carcinoma expressing substantially intenseRadiology case reports · 2024Article
- Effect of Sodium-Glucose Co-Transporter 2 Inhibitors Combined with Metformin on Pancreatic Cancer Cell Lines.International journal of molecular sciences · 2024Article
- Article
- Metabolic Rewiring and Stemness: A Critical Attribute of Pancreatic Cancer Progression.Stem cells (Dayton, Ohio) · 2023Review
- Identification of stromal microenvironment characteristics and key molecular mining in pancreatic cancer.Discover oncology · 2022Article
- Glucose transporters as markers of diagnosis and prognosis in cancer diseases.Oncology reviews · 2022Article
- The expression and survival significance of sodium glucose transporters in pancreatic cancer.BMC cancer · 2022Article
- Glucose metabolism and tumour microenvironment in pancreatic cancer: A key link in cancer progression.Frontiers in immunology · 2022Review
- Orchestration of mesenchymal plasticity and immune evasivenessFrontiers in oncology · 2022Review
- Review
- Article
- The Value ofFrontiers in medicine · 2021Article
- Article
- Dietary Polyphenols in Cancer Chemoprevention: Implications in Pancreatic Cancer.Antioxidants (Basel, Switzerland) · 2020Review
- Relationships between expression of glucose transporter protein-1 and hypoxia inducible factor-1α, prognosis andTranslational cancer research · 2020Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Increasing evidence has demonstrated that malignant cells exhibit increased glucose uptake, which facilitates survival and growth in a hypoxic environment. The glucose transporter-1 (GLUT-1) is overexpressed in a variety of malignant tumors. However, the association between GLUT-1 expression and clinicopathological factors,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.